organon's (OGN) VTAMA cream receives strong recommendation from dermatology academy

Organon & Co. (NYSE: OGN) announced that its VTAMA (tapinarof) cream received a strong recommendation from the American Academy of Dermatology in updated 2025 guidelines for treating adults with moderate to severe atopic dermatitis.

The recommendation applies to the 1% topical cream for adults with moderate to severe atopic dermatitis, the most common form of eczema. The academy's focused guideline update incorporates recently FDA-approved topical and systemic therapies into existing guidance for dermatologists.

VTAMA cream is a steroid-free, topical aryl hydrocarbon receptor agonist with no label warnings, precautions, contraindications, or restrictions on duration of use or percentage of body surface area affected. The recommendation is based on evidence from the ADORING 1 and ADORING 2 8-week clinical trials.

In December 2024, the FDA approved VTAMA cream for treating atopic dermatitis in adults and pediatric patients 2 years and older. The agency previously approved the treatment for plaque psoriasis in adults in May 2022.

Atopic dermatitis affects approximately 26 million people in the United States, with 16.5 million adults among those cases. The condition causes itchy, red, swollen, and cracked skin, often affecting arm folds, back of knees, hands, face, and neck.

Common adverse reactions for atopic dermatitis treatment include upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain, each occurring in at least 1% of patients.

The company's Phase 3 ADORING 3 48-week extension study showed the possibility of treatment-free intervals lasting an average of 80 days after treatment success, according to the press release.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• SOS Limited receives NYSE non-compliance notice over share price